ACCC highlighted that the Federal Court has ordered the manufacturers of pain relief product Voltaren Osteo Gel to give $4.5 million in fines for violations of the Australian Consumer Law.
During May 2019, the Federal court acknowledged admissions by Novartis & GSK that they made false or misleading descriptions while marketing the Voltaren Osteo Gel & Voltaren Emulgel pain relief items.
From January 2012 to March 2017, Novartis and then GSK marketed Osteo Gel as being exclusively formulated & more efficient than Emulgel in curing osteoarthritis linked pain & inflammation, even though both the products had same ingredients.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.